Working with a pharmaceutical industry client, we were part of a successful lobbying effort to get Democratic Leadership to add an exemption for orphan drugs from the proposed expansion of the 340B program as part of its reconciliation "sidecar" bill. This exemption is vitally important to both manufacturers that produce and patients who rely upon drugs for rare and ultra rare diseases, and would address a potentially dangerous, yet unintended consequence of the President's health care reform bill.